XLO Christopher James Frankenfield sold Xilio Therapeutics, Inc. shares — SEC Form 4SELLXilio Therapeutics, Inc.

Christopher James Frankenfield, Chief Financial Officer at Xilio Therapeutics, Inc. (XLO), sold 6,954 shares at $0.98 ($7K) on 2025-01-02, disclosed to the SEC on 2025-01-03.

SEC EDGAR Filing

0001415889-25-000407

View on SEC EDGAR

Trade context

Scheduled sale ($7k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.

Modest58/100

Nothing distinguishes this filing.

Opportunistic SellExercise & Sell

Filing Info

Filed2025-01-03

Traded2025-01-02

Accession0001415889-25-000407

Sourcesec_form345

Insider

NameChristopher James Frankenfield

TitleChief Financial Officer

PIT GradeInsiderUnrated

View Company View Insider

Related Trades by This Insider

Ticker	Type	Filed	Value	7d Stock	Filing
XLO	SELL	2026-01-05	$9K	—	Filing →

Get an email when an insider at XLO files

Free account. Follow XLO and up to 10 more companies.

Follow XLO for free

XLO Christopher James Frankenfield sold Xilio Therapeutics, Inc. shares — SEC Form 4SELLXilio Therapeutics, Inc.

Filing Info

Insider

Related Trades by This Insider

Trade Details

Outcomes